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6-Diazo-5-oxonorleucinea b s t r a c t
Plasmodium falciparum (PF) is the most severe malaria parasite. It is developing resistance quickly to
existing drugs making it indispensable to discover new drugs. Effective drugs have been discovered tar-
geting metabolic enzymes of the parasite. In order to predict new drug targets, computational methods
can be used employing database information of metabolism. Using this data, we performed recently a
computational network analysis of metabolism of PF. We analyzed the topology of the network to ﬁnd
reactions which are sensitive against perturbations, i.e., when a single enzyme is blocked by drugs. We
now used a reﬁned network comprising also the host enzymes which led to a reﬁned set of the ﬁve
targets glutamyl–tRNA (gln) amidotransferase, hydroxyethylthiazole kinase, deoxyribose–phophate
aldolase, pseudouridylate synthase, and deoxyhypusine synthase. It was shown elsewhere that glutam-
yl–tRNA (gln) amidotransferase of other microorganisms can be inhibited by 6-diazo-5-oxonorleucine.
Performing a half maximal inhibitory concentration (IC50) assay, we showed, that 6-diazo-5-oxonorleu-
cine is also severely affecting viability of PF in blood plasma of the human host. We conﬁrmed this by an
in vivo study observing Plasmodium berghei infected mice.
 2013 Elsevier B.V. All rights reserved.1. Introduction
In the present, half of the world’s population are at risk of ma-
laria. According to WHO, there were about 3 billion people threa-
tened by malaria in 109 countries and territories from South
America to the Indian peninsula. Malaria kills about 3 million peo-
ple each year, of which more than 1 million are children under the
age of ﬁve. In addition, up to half a billion people suffer from the
effects of malaria (Snow et al., 2001). Although there are several
different treatments for malaria, the parasite is becoming increas-ingly resistant to conventional antimalarial drugs. This has contrib-
uted to increasing morbidity and mortality. Four species of the
Plasmodium genus cause humanmalaria. Among these, Plasmodium
falciparum (henceforth P. falciparum or PF) inﬂicts the most mortal-
ity and is responsible for about 90% of malaria deaths (Snow and
Omumbo, 2006). The latest additions to the armoury of antimalar-
ial drugs are artemisinins. These are remarkably potent against the
asexual blood stage of the parasite’s life cycle and have been
shown to be effective against all stages (except the liver stages)
of the parasite’s lifecycle (Delves et al., 2012). Therefore, artemisi-
nin-based combination therapies (ACTs) have now been adopted
globally as the ﬁrst line of treatment. It is to note that artemisinin
monotherapy was withdrawn to protect the class against the
emergence of resistance (WHO, 2005). Currently, ACTs with mos-
quito-control measures such as insecticide treated bed nets have
driven down malaria rates across sub-Saharan Africa. But the fact
Fig. 1. An example to illustrate the computational essentiality feature we used.
Rectangles represent reactions, circles represent metabolites and lines represent
either consumption or production of metabolites by reactions. The ﬁlled rectangle
(reaction 2) represents the observed reaction. Reaction 2 is a chokepoint reaction
because it uniquely produces metabolite C and there is no deviation (or alternative
pathways) from B to C. Therefore, blocking reaction 2 may severely harm the cell.
Table 1
List of potential drug targets from Fatumo et al. (2009) and our new analysis results.
EC Reaction Chokepoint
2.1.2.9 Methionyl–tRNA formyltransferase Y*
2.4.1.119 Dolichyl–diphosphooligosaccharide–protein
glycosyltransferase
2.4.2.11 Nicotinate phosphoribosyltransferase
2.4.2.30 NAD(+) ADP–ribosyltransferase
6.3.5.7 Glutamyl–tRNA(Gln) amidotransferase Y
2.5.1.46 Deoxyhypusine synthase Y
2.7.1.1 Hexokinase
2.7.1.35 Pyridoxal kinase
2.7.1.50 Hydroxyethylthiazole kinase Y
2.7.4.7 Phosphomethylpyrimidine kinase
2.7.4.9 Thymidylate kinase
2.7.7.2 FMN adenylyltransferase
2.7.8.- Cardiolipin synthetase
2.7.8.11 CDP-diacylglycerol–inositol 3-
phosphatidyltransferase
3.1.2.6 Hydroxyacylglutathione hydrolase
3.5.1.19 Nicotinamidase
4.1.2.4 Deoxyribose–phosphate aldolase Y
4.2.1.17 Enoyl–CoA hydratase
4.2.1.60 3-Hydroxydecanoyl-[acyl-carrier protein]
dehydratase
4.2.1.70 Pseudouridylate synthase Y
6.1.1.19 Arginine–tRNA ligase
6.2.1.3 Long-chain-fatty-acid-CoA ligase
*
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are unknown or controversial (Schlitzer, 2008) and delayed rates
of parasite clearance after administration of ACTs are already evi-
dent near the Thai–Cambodian border, a hotbed of multidrug resis-
tance. So time is for alternative treatments. For the discovery and
development of antimalarial drugs, the application of computa-
tional methods and predictions has shown beneﬁcial impact. It is
well known that the ability to discover drug or vaccine targets
can be enhanced from our understanding how enzyme dis-func-
tion can affect metabolic pathways (Folger et al., 2011; Plaimas
et al., 2010, 2008). Metabolism is the central cellular process and
its malfunction is a major contributor to harm the parasite. The
discovery of genomic information of a species allows now for a
comprehensive genome-scale reconstruction of its metabolism.
For PF, the necessary data for reconstruction can be retrieved from
different databases, in particular BioCyc (Karp et al., 2005), The Ma-
laria Parasite Metabolic Pathways (MPMP) (Ginsburg, 2006), The
Kyoto Encyclopedia for Genes and Genomes (KEGG) (Kanehisa
et al., 2008), and PlasmoDB (Aurrecoechea et al., 2009). The pros-
pect of understanding the relationship between the genome and
the physiology of an organism is an important incentive to recon-
struct metabolic networks and to perform network based analyses
of the parasite’s metabolism to identify effective drug targets.
We performed recently a computational network analysis of
metabolism of PF using these databases. The topology of the net-
work was analyzed to observe the robustness of the parasite’s met-
abolic network when single enzymes were blocked by mimicking
in silico their inhibition by drugs. This analysis led to the identiﬁca-
tion of 22 potential drug targets (Fatumo et al., 2009). We now
used a reﬁned network including also enzymes of the human host
to get less false–positives which function may be substituted by
the human enzymes. Performing a computational chokepoint
analysis, we yielded a list of ﬁve potential targets (glutamyl–tRNA
(gln) amidotransferase, hydroxyethylthiazole kinase, deoxyribose–
phophate aldolase, pseudouridylate synthase, and deoxyhypusine
synthase). It was shown in Chlamydomonas reinhardtii that 6-dia-
zo-5-oxonorleucine (DON) is an effective inhibitor of glutamyl–
tRNA (gln) amidotransferase (Jahn et al., 1990). We performed an
experimental viability assay (IC50 analysis) and could show that
DON suits as a valid agent against PF (laboratory strain Dd2). This
was conﬁrmed by an in vivo study using Plasmodium berghei
infected Swiss albino mice.Y: essential according to the chokepoint analysis.2. Results and discussion
2.1. A computational analysis identiﬁes ﬁve potential drug targets
interfering metabolism of PF
Twenty-two predicted drug targets (enzymes) for P. falciparum
were extracted from our former computational analysis (Fatumo
et al., 2009). We performed a network analysis using a recon-
structed metabolic network which included PF and human en-
zymes (see Section 4, and as described previously (Fatumo et al.,
2011)) to get an improved precision. We analyzed the topology
of the network and used the established method of chokepoint
analysis (Plaimas et al., 2008; Yeh et al., 2004). Brieﬂy, the choke-
point analysis tests if after deletion of an enzyme, either one of its
products cannot be produced (by any other enzyme) anymore, or if
one of its substrates cannot be consumed any more. The enzyme is
predicted to be essential (a chokepoint reaction) if such substrates
or products are determined (see Fig. 1). With this analysis, we
yielded ﬁve enzymes: glutamyl–tRNA (gln) amidotransferase (EC
6.3.5.7), hydroxyethylthiazole kinase (EC 2.7.1.50), deoxyribose–
phophate aldolase (EC 4.1.2.4), pseudouridylate synthase (EC
4.2.1.70), and deoxyhypusine synthase (EC 2.5.1.46) (Table 1,marked as Y). We now wanted to use these predictions to identify
small compounds tipping PF. For this, we searched for inhibitors
that were effective to block an enzyme in other organisms. It was
reported that DON successfully inhibited glutamyl–tRNA (Gln)
amidotransferase of C. reinhardtii (Jahn et al., 1990). We did a
homology analysis of the gene encoding glutamyl–tRNA (gln)
amidotransferase in C. reinhardtii (gat1), in P. falciparum, and the
human host. We found signiﬁcant similarity between all three
organisms (Fig. 2) making it for our investigations suitable, but
note that homology to the human host may make the identiﬁcation
of speciﬁc drugs challenging (which was out of the scope of our
study). Homologs of hydroxyethylthiazole kinase could not be
found. Hydroxyethylthiazole kinase participates in the biosynthe-
sis of thiamine (vitamin B1). It was reported that Plasmodium can
obtain thiamine from the extracellular space (Wrenger et al.,
2008) and the parasite may hence be independent of this reaction.
For the other enzymes we could not ﬁnd known inhibitors. There-
fore we restricted our experimental analysis to DON. It is to note
that DON can act on several glutamine metabolizing enzymes. A
literature summary about other metabolic effects of DON will be
given below.
Fig. 2. Homology comparison of the coding genes for glutamyl–tRNA (gln)
amidotransferase.
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Glu–tRNA (gln) amidotransferase (EC 6.3.5.7) is needed to syn-
thesize glutamyl–tRNA–gln. Glutamyl–tRNA–gln serves as a build-
ing block for protein synthesis and this is essential for PF to
proliferate. Glutamyl–tRNA–gln can be generated from tRNA and
glutamine by two ways, either directly using glutaminyl–tRNA
synthetase (EC 6.1.1.18), or by two steps using glutamyl–tRNA syn-
thetase (EC 6.1.1.24) and glu–tRNA (gln) amidotransferase (EC
6.3.5.7). The two-step synthesis has been observed in mitochondria
and bacilli (Ibba and Soll, 2000). Our network did not include glu-
taminyl–tRNA synthetase (EC 6.1.1.18) as we did not ﬁnd it in the
used databases. Still, glu–tRNA (gln) amidotransferase (EC 6.3.5.7)
was found in Biocyc and MPMP for P. falciparum, and there exists a
coding gene for glu–tRNA (gln) amidotransferase (PFD0780w).Fig. 3. The IC50 results of (a) DON and (b) quinGlu–tRNA (gln) amidotransferase (EC 6.3.5.7) is only useful for PF
if the two step pathway exists. We wanted to ﬁll the gap for the
two step pathway. To ﬁnd putative genes coding for glutamyl–
tRNA synthetase (EC 6.1.1.24), we performed an NCBI blast search
using glutamyl–tRNA synthetase (EC 6.1.1.24) from Bacillus subtillis
as query (WP_014475595.1) and the non-redundant protein se-
quence database of PF as the sequence database. We yielded
XP_001350283.1 with good homology (E-value: 2E-91).
XP_001350283.1 is annotated as putative glutamate–tRNA ligase.
We ﬁnally added glutamyl–tRNA synthetase (EC 6.1.1.24) to our
network (see Supplementary 1 list of reactions). Performing a
chokepoint analysis with the new network yielded the same ﬁve
reactions, and in addition glutamyl–tRNA synthetase (EC
6.1.1.24) (on which we did not follow up in this study), conﬁrming
glu–tRNA (gln) amidotransferase (EC 6.3.5.7) to be essential for PF.2.3. DON successfully affected the parasite’s viability in human blood
cultures
Glutamyl–tRNA(Gln) amidotransferase catalyzes glutamyl–
tRNA Gln into glutaminyl–tRNA (gln) which is used for protein
synthesis. DON is a structural analog of glutamine and inhibits irre-
versibly glutamine amidotransferases of several organisms (Clark
et al., 1987; Jahn et al., 1990). DON is a non proteinogenic amino
acid. It was originally derived from Streptomyces (Dion et al.,
1956) and showed anticancer effects in animal models (Yoshioka
et al., 1992). We performed a half maximal inhibitory concentra-
tion (IC50) study and found that DON showed excellent anti-
malarial activity in vitro when applied against P. falciparum Dd2
(3–4  e7 M, Fig. 3a). We performed positive control experimentsine and chloroquine as positive controls.
Fig. 4. Effects of DON on parasitemia in mice 24 h after treatment.
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slightly better dose response of 9.2  e08 and 4.7  e08 M,
respectively (Fig. 3b).2.4. DON treatment reduced parasitemia in mice
To ﬁnd out if DON suits for affecting parasitemia in vivo, we per-
formed a mouse model study. P. berghei infected mice were in-
jected intraperitoneally with DON dissolved in normal saline and
parasitemia was observed 24 and 72 h after treatment. Fig. 4 shows
the results for 24 h and Fig. S1 of Supplementary 2 the results for
72 h after treatment. 24 h after treatment, 50% reduction of P. berg-
hei was observed when administering 12.5 mg/kg DON, and even
80% reduction 72 h after treatment. Interestingly, at very low con-
centrations (<6 mg/kg) we observed an increase of parasitemia
after 24 h. DON did not severely harm our animal models as the
treated animals survived until the time of writing (>6 weeks).
Again chloroquine showed a better performance of 80% reduction
of parasitemia (24 h after treatment) at comparable concentrations
(10 mg/kg). 72 h after treatment, the effect of DON and chloro-
quine was comparable (80–90% reduction). None of the infected
control animals survived 72 h.2.5. DON can effect other glutamine metabolizing enzymes
We performed an elaborate literature study for DON to ﬁnd evi-
dence for DON effecting other enzymes besides glutamyl–tRNA
(gln) amidotransferase. In several studies, glutamine:fructose-6-
phosphate amidotransferase (GFAT), the rate-limiting enzyme for
hexosamine ﬂux, was inhibited using DON (Goldberg et al., 2002;
James et al., 2010, 2002; Lim and Chang, 2006). However, these
studies used higher concentrations (James et al.: 10 lM, Lim
et al.: 40–75 lM, Goldberg et al.: 20 lM, James, Tang et al.:
40 lM) when compared to our analysis (IC50 = 0.4 lM). Only very
high concentrations of DON inhibited NADH-dependent glutamate
synthase (NADH-GOGAT; EC 1.4.1.14): 1 mM resulted in 11% activ-
ity, and 0.5 mM showed no effect (Hirayama et al., 1998). Using
2 mM DON yielded 98% reduced CTP synthetase activity (Robertson,
1995). Interestingly, Hofer et al. reported to inhibit the prolifera-
tion of cultured trypanosomes using DON at low concentrations
(25 mg DON/kg, i.e., twice as much as we used in our in vivo study)
and treatment of Trypanosoma brucei infected mice with DON re-
duced the number of trypanosomes in the blood to undetectablelevels. They found that DONmainly affected de novo purine biosyn-
thesis in mammalian cells (Hofer et al., 2001). Alkylation of guano-
sine 50-monophosphate (GMP) synthetase with DON inactivated
GMP synthetase (concentration of DON: 16 lM) (Zalkin and Truitt,
1977). It was shown that DON is an inhibitor of glutaminase
(Hartman and McGrath, 1973). Summing up, DON is an unspeciﬁc
inhibitor and the in vitro and in vivo effects we obtained for malaria
treatment need further investigation to better identify the molec-
ular mechanisms of DON. In addition, we performed spectrophoto-
metric enzyme assays for b-NAD synthetase and uracil
phosphoribosyl transferase. b-NAD synthetase (EC 6.3.5.1) is part
of the NAD biosynthesis pathway and metabolizes deamido-
NAD+ and L-glutamine to NAD+ and L-glutamate. We wanted to ob-
serve b-NAD synthetase to ﬁnd out if DON acts as its inhibitor
(competing with its substrate glutamine). For higher concentra-
tions (25 and 50 mg/kg), the activity was reduced (40 instead of
56 units/mg protein) in liver of DON treated mice (Supplementary
2, Fig. S2a, supplementary material). We therefore cannot exclude
that DONs inﬂuence on b-NAD synthetase may have inﬂuenced the
in vitro culture and in vivo parasitemia reduction. Interestingly,
72 h after treatment, the cells from the treated and untreated mice
showed the same activity when regarding DON treatment of
25 mg/kg (our treatment for parasitemia: 12.5 mg/kg). Further
analyses on other glutamine metabolizing enzymes will be neces-
sary to shape out the concrete mode of action of DON. Further, we
observed the activity of uracil phosphoribosyl transferase. Uracil
phosphorybosyltransferase (UPRT, EC 2.4.2.9) plays an important
role in the pyrimidine salvage pathway since UMP is a common
precursor of pyrimidine nucleotides. The activity of UPRT was
therefore assayed to observe a potential metabolic shift in pyrim-
idine metabolism. Interestingly, mice treated with DON showed
higher activity (82 instead of 30 units/mg protein) of uracil phos-
phoribosyl transferase (Supplementary 2, Fig. S2b) hinting for in-
creased pyrimidine metabolism. Unfortunately, we were not able
to perform such activity measures for glutamyl–tRNA (gln)
amidotransferase.3. Conclusion
We employed a computational analysis to identify potential tar-
gets in the parasite-host metabolic network. We predicted glutam-
yl–tRNA (gln) amidotransferase, hydroxyethylthiazole kinase,
deoxyribose–phophate aldolase, pseudouridylate synthase, and
Table 2
Statistics of the reconstructed model.
Number of reactions 723
Number of metabolites 842
Number of links between reactions 8694
Density of the network 3.3%
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P. falciparum. Selecting DON as a potential inhibitor for glutamyl–
tRNA (gln) amidotransferase, we observed a good dose response
for DON when measuring its effectiveness on viability of
Plasmodium in human blood culture by a half maximal inhibitory
concentration (IC50) assay and in mouse models. These are promis-
ing results hinting for DON to be used as an anti-malaria drug.
However, DON can have severe site effects. DON has been observed
to alter cell cycle and may increase mutagenesis, in particular dur-
ing development. It was shown that DON prevented G2-M phase
transition in oocytes of Xenopus laevis (Dehennaut et al., 2007).
DON caused renal dysplasia of chicken and impaired their embryo
formation (Spencer and Maizels, 1987). Therefore DON needs more
investigation in vivo. It may only be used at low concentrations and
in combination with other drugs such as artemisinins. In addition,
follow up studies are needed to elucidate the concrete mechanism
of DON. DON can act on a variety of glutamine metabolizing
enzymes and this may be better estimated performing spectropho-
tometric assays for more potentially effected enzymes. Also studies
estimating bond-tightness may improve concretizing effects of
DON. Finally, further in vivo and culture based research should
include also other strains of Plasmodium to determine a more
general applicability of DON for treating malaria.4. Materials and methods
4.1. Reconstructing the metabolic network and chokepoint analysis
The network was put up as described previously (Fatumo et al.,
2011) using the databases of PlasmoCyc version 11.6 (Karp et al.,
2005) and Malaria Parasite Metabolic Pathways (MPMP, see
(Ginsburg, 2006)). All reactions were set as reversible to avoid false
negatives if reactions were wrongly annotated to be irreversible. It
is to note that considering all reactions to be reversible may yield
additional false positives and may need more literature investiga-
tion of the results. The network comprised of reactions from
P. falciparum (PlasmoCyC and MPMP) and human. Reactions were
only selected if a coding gene was assigned to them. The human
metabolism was extracted from the database HumanCyc version
11.6 (Romero et al., 2005). The MPMP database consisted of 4806
genes with a total of 1265 enzyme ids. Out of all genes in MPMP,
2033 genes mapped with their corresponding reactions in
PlasmoCyc. The network was constructed as a bipartite graph
consisting of alternating nodes of enzymes and metabolites. If a
metabolite was a substrate of one reaction and a product of
another reaction these reactions were linked via this metabolite.
Hub compounds such as water, oxygen, ATP, ADP, and co-enzymes
were discarded to avoid unspeciﬁc links. Finally, we yielded
723 (reversible) reactions (modeled as 1446 considering both
directions). A list of all reactions is given in the supplementary
material (Supplementary 1 List of reactions, including also reaction
glutamyl–tRNA synthetase (EC 6.1.1.24), see Section 2). Table 2
shows the statistics for the network.Fig. 5. Flowchart for the chokepoint procedure (to ﬁnd out if reaction r is a
chokepoint).4.2. Chokepoint analysis
A reaction that uniquely consumed or produced a certain
metabolite in the metabolic network was considered to be a choke-
point as described elsewhere (Rahman and Schomburg, 2006; Yeh
et al., 2004; Plaimas et al., 2008). As each reaction was considered
to be reversible, an in- or out-degree of 2 of a substrate or a prod-
uct of the considered reaction hinted for the reaction to be a choke-
point reaction (taking into account the links to the considered
reaction). Fig. 5 shows a ﬂowchart of the algorithm and Fig. 1 illus-
trates the principle idea.4.3. Finding inhibitors
After potential target candidates were selected, their effective
inhibitors were identiﬁed which were reported to block an enzyme
in other organisms. The inhibitors were collected searching the
Brenda Enzyme database (Schomburg et al., 2013), Drugbank
(Wishart et al., 2008) and Sigma (http://www.sigma.com). DON
was found bei Jahn and coworkers to be an effective inhibitor of
glutamyl–tRNA(Gln) amidotransferase of C. reinhardtii (Jahn et al.,
1990). This compound was further investigated and ordered from
Sigma (http://www.sigma.com).4.4. Parasite cultures for the in vitro anti-plasmodial assay
RPMI 1640 culture medium supplemented with L-glutamine,
35 mM HEPES and 23 mM NaHCO3, stored at 4 C (Invitrogen) P.
falciparum Dd2 was used. The parasites were cultured in A+ human
erythrocytes at a hematocrit of approximately 5% in Petri dishes of
either 10 cm diameter containing 15 ml of HEPES-buffered RPMI
medium supplemented with 10% human serum type A+, 20 lg/ml
of gentamicin and 100 lM of hypoxanthine. The parasite cultures
were incubated in an atmosphere of 3% CO2, 5% O2, 92% N2, and
95% humidity at 37 C. Every two to three days, the parasitemia
determined by Giemsa-stained blood smears and medium was ex-
changed. By the time the parasitemia had reached 5–10%, the cul-
ture was split in order to avoid parasite death due to high levels of
toxic metabolites in the medium. Drug activity in vitro was deter-
mined based on the inhibition of the incorporation of [3H]-hypo-
xanthine into parasite nucleic acids according to the method of
Desjardins et al. (1979). Brieﬂy, one hundred-microliter parasite
culture medium containing serially diluted drug were placed in the
wells of 96-well microtiter plates. Then, one hundred-microliter
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(2 – 6 h post invasion) at a parasitemia of 0.5% and a hematocrit
of 2.5% were added to the wells. [3H]-hypoxanthine was added
48 h later to monitor parasite viability. Reactions were stopped
24 h later, and parasitemia were expressed as a percentage of the
control (without drug).4.5. DON treatment of P. berghei infected mice
Chemicals were obtained from Sigma–Aldrich, USA. P. berghei
infected mice (8 weeks old Swiss albino mice) were injected intra-
peritoneally with DON dissolved in normal saline (saline concen-
tration was 0.9% (w/v) NaCl solution). The treatment groups were
as follows (each n = 5): group 1: control (mice administered with
normal saline), group 2: 1.56 mg DON/kg body weight, group 3:
3.125 mg DON/kg body weight, group 4: 6.25 mg DON/kg body
weight, group 5: 12.50 mg DON/kg body weight, group 6:
25.00 mg DON/kg body weight, and group 7: 10.00 mg Chloro-
quine/kg body weight. Dosages were chosen in accordance to early
work on DON administered to mice to treat cancer (Barclay and
Phillipps, 1966) and T. brucei (Hofer et al., 2001). To diagnose par-
asitemia, blood smear was prepared from the tail blood of the mice
after 24 h of drug administration. Thick and thin ﬁlms were ﬁxed
with methanol, air-dried and stained with Giemsa stain. Parasite-
mia, i.e., Parasite density per microliter of blood, was estimated
from the thick ﬁlm, taking the number leucocytes (WBC) per
microliter of blood as 8000 and was expressed as follows:
Parasite density= lL of whole blood ¼ Parasite countNumber of WBC Counted 8000 as
described by Olasehinde et al. (2012).4.6. Effect of DON on enzymes of nucleic acid metabolism
DON was dissolved in normal saline which was administered
intraperitoneally to pathogen free mice that were grouped as fol-
lows (n = 12 of each group): group 1: control (mice were adminis-
tered with normal saline), group 2: 25 mg DON/kg body weight,
and group 3: 50 mg DON/kg body weight. Six mice from each
group were sacriﬁced after 24 h of drug administration and six
were sacriﬁced after 72 h. The sacriﬁce was done under light ether
anesthetic. Liver was excised into ice cold saline and homogenized
in ice cold 0.25 M sucrose, 1 mM EDTA, 10 mM HEPES-NaOH, pH
7.4 containing SIGMAFAST™ Protease Inhibitor. The homogenate
was centrifuged at 800g for 15 min and the supernatant used for
the activity assays of the enzymes. Spectrophotometric methods
were used to assay the enzyme’s activities as follows: Uracil phos-
phoribosyl transferase (Liu et al., 2000), and b-NAD synthetase (Yi
and Dietrich, 1972). The Lowry protein assay method (Lowry et al.,
1951) was used to determine protein concentration and the activ-
ity expressed as units per mg protein. Basically, the activity of ura-
cil phosphoribosyltransferase was measured by monitoring the
conversion of uracil to UMP at 271 nm. The assay solution (1 ml)
contained 5 mM MgCl2, 1.5 mM phosphoribosyl pyrophosphate,
0.1 mM uracil, and 50 mM Tric–HCl, pH 7.8 buffer. The reaction
was initiated by the addition of 20 lL of liver homogenate and
activity was deﬁned as the amount of enzyme that catalyzed the
formation of 1 nmol of UMP/min (Liu et al. 2000). The activity of
b-NAD synthetase was measured by monitoring the rate of NAD
formation. The reaction solution contained 1 mM deamido-NAD+,
2 mM ATP, 0.1 mM (NH4)2SO4, 5 mM MgCl2, 56 mM KCl, 50 mM
Tris–HCl buffer, pH 8.0 (at 37 C). The reaction was initiated by
addition of 100 lL of liver homogenate and terminated after 60 s
in boiling water. NAD formed was determined by employing alco-
hol dehydrogenase (Yi and Dietrich, 1972). Data obtained was ana-
lyzed using Analysis of Variance (ANOVA) followed by the Duncan
Multiple Range Test (p < 0.05).Author’s contributions
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